The efficacy and safety of remimazolam tosylate in children undergoing enteroscopy: a single center, randomized, single blind, propofol positive control study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043125

Enrollment

Unknown

Registered

2021-02-05

Start date

2021-11-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

R1:Remimazolam 0.1mg/kg

R2:Remimazolam 0.15mg/kg

R3:Remimazolam 0.2mg/kg

C:propofol 3mg/kg

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Aged 6-12 years; 2.ASA I-II; 3.undergong enteroscopy.

Exclusion criteria

Exclusion criteria: 1. Patients with known allergies or contraindications to benzodiazepines, flumasinil, and opioids; 2. Patients with airway management difficulties, such as chin distance 33 kg/m2); 4. The child has myasthenia gravis, intellectual retardation or neurological, mental and psychological diseases;Unable to communicate in Chinese or cooperate with investigators for other reasons.

Design outcomes

Primary

Measure	Time frame
Dose of Remazolam during Induction and maintenance of anesthesia;	—

Secondary

Measure	Time frame
Safety of use of Remazolam in children;	—

Countries

China

Contacts

Public ContactSiwei Wei

Hunan Children's Hospital

wsw769850382@qq.com+86 18588857577

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026